Newer antidepressants offer similar efficacy

	Tweet

Second-generation antidepressants differ little in their efficacy for treating major depressive disorder, according to a report in the Annals of Internal Medicine.

The results of studies that have compared these drugs suggest “only minimal differences in efficacy, although some of the drugs come with an increased risk of certain side effects,” said Dr. Richard A. Hansen from University of North Carolina at Chapel Hill. “Understanding the likelihood of these side effects and matching this information with patient’s lifestyle and preferences may help improve drug treatment of Depression."

Hansen and his colleagues reviewed the medical literature in an effort to compare the effectiveness and tolerability of six selective Selective Serotonin Reuptake Inhibitors (SSRI’S) and four other second-generation antidepressants: bupropion (Wellbutrin), duloxetine (Cymbalta), mirtazapine (Remeron), and venlafaxine (Effexor).

None of the SSRIs appeared to differ significantly in effectiveness, speed of patient response, or quality of life outcomes, the authors report. Most trials also showed SSRIs and other second-generation antidepressants to have similar efficacy, speed of response, and resulted in comparable patient quality of life, the report indicates.

Overall, side effects occurred at similar rates among antidepressants, the researchers note, though individual antidepressants emerged as having higher rates of specific side effects (more nausea and vomiting with venlafaxine and fewer sexual side effects for bupropion, for example).

“Additionally, some medications differ in cost and dosing interval,” Hansen said. “Without understanding a patient’s preferences for these aspects of treatment, it’s difficult to make a recommendation.”

“In the absence of patient preferences,” Hansen said, “I would probably start with generic fluoxetine (Prozac), citalopram (Celexa), or Bupropion.”

Future research on drug treatment for patients with major Depression “should include large, high-quality effectiveness trials,” the investigators add. “Choosing the agent that is most appropriate for a given patient is difficult.”

SOURCE: Annals of Internal Medicine, September 20, 2005.

RELATED STORIES:
Early ADHD diagnosis a risk factor for depression   Depressed anorexics may drop out of family therapy   Hay Fever Linked to Depression   Combat may raise eating disorder risk in women   VCU Finds Risk for Depression Similar in Men and Women   Depression can be fatal, particularly for women   Depressed People Gain More from Getting Married   Binge drinking affects attention and working memory in young university students   Genomic catastrophe causes developmental delay, cognitive disorders   Mental Illness and Drug Addiction May Co-occur Due to Disturbance in the Brain’s Seat of Anxie   Do video games fuel mental health problems?   Sinai Physiatrist Enthusiatic About Word Addition   As Antidepressants Begin to Work, Hopelessness Can Linger   New research may lead to improved diagnosis of autism   Littlest couch potatoes face mental health risks

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]